QualityStocksNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Signs Definitive Loan Restructuring Agreement with EIB Converting Debt into Equity
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the signing of a definitive Loan Restructuring Agreement with the European Investment Bank (“EIB”), its lender. The agreement also included an amendment and restatement to the Finance Contract between the parties. According to the announcement, an amount equal to approximately €26.6 million (approximately $29 million), including interest accrued to date, owned by Scinai to EIB under the finance contract, will be converted into 1,000 preferred shares, no par value per share, of…